Skip to main content
Caplight Logo









Syndex Bio

Syndex Bio

Private
CambridgeHealthcare & Life Scienceshttps://www.syndex.bio/

Last Round

Seed

Feb 23, 2026

Total Funding Raised

$15.5M

Company Overview

Syndex Bio is a biotechnology company developing a platform that brings together molecular technologies, instrumentation, and AI to accelerate the understanding, diagnosis, and treatment of disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

mcPCRmethyl-copying PCRDNA methylation analysisliquid biopsyearly cancer detectionepigeneticsmolecular diagnosticsoncology diagnosticsepigenetic biomarkersdiagnostic platformnon-invasive diagnosticsDNA amplificationPCR technologydiagnostic test developmentAI-driven protein engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Syndex Bio Comparables

Compare Syndex Bio with similar companies based on industry and business-model similarity.

Syndex Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Epigentek Group Inc.
69%
biomodal
69%
Thermo Fisher Scientific Inc.
65%

Syndex Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 23, 2026

Key People

Founding team and executive leadership

Geoff Smith

CEO and Co-Founder

Founding Team

Jason Betley

Chief Product Officer

Executive Team

Syndex Bio Investors

Notable investors and investment history

Syndex Bio investors
InvestorRounds
ARCH Venture PartnersSeed
+ND CapitalSeed
Meltwind AdvisorySeed
OMX VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 6, 2026

    Grew 28% QoQ, from 18 to 23 employees.

  • Jan 8, 2026

    Grew 20% QoQ, from 15 to 18 employees.

Syndex Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Syndex Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Syndex Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range28
Year Founded2022
Last FundingFeb 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?